Global Viral Clearance Services Market Size study & Forecast, by Method (Viral Removal, Viral Inactivation), by Application (Recombinant Proteins, Tissue & Blood-Derived Products, Vaccines, Others), by End-User (Biopharmaceuticals, Contract Research Organ

Global Viral Clearance Services Market Size study & Forecast, by Method (Viral Removal, Viral Inactivation), by Application (Recombinant Proteins, Tissue & Blood-Derived Products, Vaccines, Others), by End-User (Biopharmaceuticals, Contract Research Organizations, Academic Research Institutes), and Regional Analysis, 2023-2030

Global Viral Clearance Services Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than 15% over the forecast period 2023-2030. The generation of recombinant proteins, glycoproteins, tissue- and blood-derived products, medicinal devices, and monoclonal antibodies all depend on the viral clearance process. This is explained by the possibility of bacterial and fungal contamination, chemical contaminants, and viral contamination in these items. The market for viral safety practices is influenced by the viral clearance and assessment processes since they are important phases in product safety. The market growth is propelled by the increasing need for Viral Clearance, growing Demand for Specialty Drugs and rise in Research and Development Funding.

The expansion of the industry under study is further aided by increased financing for medicines across the United States. The American pharmaceutical sector annually develops a wide variety of novel drugs with important clinical benefits. Many of those drugs are expensive, which raises the expense of healthcare for both the federal government and the private sector. Through Operation Warp Speed and the Biomedical Advanced Research and Research Authority, the federal government in the United States funded USD 11 billion towards late-stage vaccine research and an increase in manufacturing capacity in 2020. Moreover, growth in demand in pharmaceutical and biotechnological industries and an increase in the number of mergers and acquisitions enhance the market opportunities over the years. However, the lack of Approval for Outsourcing of Preclinical Procedures stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Viral Clearance Services Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. The North American region is currently dominating the viral clearance services market due to the presence of many pharmaceutical and biotech companies, growing government funding for research and development activities, and a well-established healthcare infrastructure. However, the Asia-Pacific region is expected to be the fastest-growing region in the viral clearance services market. The growth in this region can be attributed to the increasing demand for biopharmaceuticals, the growing number of Contract Research Organizations (CROs), and the increasing outsourcing of biopharmaceutical manufacturing to countries such as China and India

Major market player included in this report are:
Charles River Laboratories, Inc.
Labor Dr. Merk & Kollegen GmbH
Merck KGaA
Texcell SA
WuXi AppTec
Sartorius AG
Eurofins Scientific
Bioscience Laboratories
Vironova AB

Recent Developments in the Market:
 In September 2022, Merck inaugurated a viral clearance (VC) lab as a part of the initial construction phase of its new EUR 29 million China Biologics Testing Centre.
 In April 2022, Abzena, a partner research organisation (PRO), =announced the launch of a biologics testing facility close to the company's biologics process development and manufacturing base in San Diego, California. Partners will have access to viral clearance studies, cell-based and PCR safety testing, and IND, IMPD, BLA, and MAA submissions through the facility.

Global Viral Clearance Services Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered – Method, Application, End user, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Method:
Viral Removal
Viral Inactivation
By Application:
Recombinant Proteins
Tissue and Blood Derived Products
Vaccines
Other
By End User:
Biopharmaceuticals
Contract Research Organizations
Academic Research Institutes
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned

Charles River Laboratories, Inc.
Labor Dr. Merk & Kollegen GmbH
Merck KGaA
Texcell SA
WuXi AppTec
Sartorius AG
Eurofins Scientific
Bioscience Laboratories
Vironova AB

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.